Quick Answer
Werewolf Therapeutics, Inc. reported Total Assets of $69.40 million for the year ending 2025.
- Werewolf Therapeutics, Inc. showed a decrease of -45.3% in Total Assets from 2024 to 2025.
- This data is from Werewolf Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $89.44 million | Q2 2021: $190.42 million | Q3 2021: $178.38 million | Q1 2022: $164.63 million | Q2 2022: $175.33 million | Q3 2022: $172.42 million | Q1 2023: $195.07 million | Q2 2023: $185.24 million | Q3 2023: $176.39 million | Q1 2024: $177.60 million | Q2 2024: $153.70 million | Q3 2024: $140.04 million | Q1 2025: $107.24 million | Q2 2025: $92.57 million | Q3 2025: $79.63 million.
- Over the full 6 years of available data (2020 to 2025), Werewolf Therapeutics, Inc.'s Total Assets has declined by 28.0%.
- Historical annual values: Fiscal year 2025: $69.40 million | Fiscal year 2024: $126.93 million | Fiscal year 2023: $174.83 million | Fiscal year 2022: $160.25 million | Fiscal year 2021: $179.25 million | Fiscal year 2020: $96.40 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: